Abstract
Background It is well known that patients with advanced non-squamous non-small cell lung cancer (NSCLC) benefit substantially from platinum-based chemotherapy containing pemetrexed (pem/platinum ChT). Additionally, maintenance therapy with pemetrexed further improves survival in patients with clinical benefit (CB) to induction Cht. Evidence based data show that using pem instead of gemcitabine and maintenance therapy approach improves survival rates in pts with advanced non-squamous NSCLC to around 13 months (mo). The aim of our observational study was to evaluate the efficacy of first line pem/platinum in advanced non-squamous NSCLC treated in routine clinical practice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
